For customized immunoassay development, ACROBiosystems offers MMAE-specific antibodies, Anti-MMAE&MMAF antibodies, multiple labeled formats, and a four-clone screening panel. The MMAE-ADC Quantitative Detection ELISA Kit provides a preconfigured method for measuring payload-conjugated MMAE ADCs in cynomolgus monkey serum or plasma. AGLink® MMAE conjugation kits additionally support the preparation of DAR2 and DAR4 ADCs at 1 mg or 5 mg antibody scales.

ACROBiosystems MMAE-specific rabbit monoclonal antibodies have been evaluated with Disitamab Vedotin in target-capture ELISA assays using 100% human serum. The HRP-conjugated Anti-MMAE&MMAF antibody has also been evaluated with Disitamab Vedotin and immobilized HER2 under the same matrix condition. These results support assay feasibility, while sensitivity, accuracy, precision, and matrix effects should be validated for each intended bioanalytical method.

A: Format selection should follow both the required payload specificity and the planned assay architecture. An unconjugated antibody provides flexibility for customized labeling or secondary detection, while biotinylated and HRP-conjugated Anti-MMAE&MMAF antibodies support streptavidin-based and direct enzyme-detection formats, respectively. Payload specificity should be confirmed before selecting the conjugation format because labeling does not determine MMAE/MMAF cross-reactivity.

Linker structure, conjugation context, and payload accessibility may affect how an Anti-MMAE antibody recognizes a particular ADC. The ACROBiosystems Anti-MMAE Antibody Screening Panel contains four MMAE-specific rabbit monoclonal antibodies—M1H05, M1H09, M1G04, and M1D12—with different recognition characteristics. Testing the panel with the intended ADC and sample matrix helps identify a suitable clone before developing the full assay.

MMAE and MMAF are structurally related auristatin payloads that share common molecular features. Whether an antibody distinguishes between them depends on its epitope and how the payload is presented within the linker–ADC structure. Cross-reactivity should therefore be evaluated using relevant MMAE- and MMAF-conjugated controls. ACROBiosystems provides both Anti-MMAE&MMAF antibodies and MMAE-specific antibody clones for different specificity requirements.

A: An Anti-MMAE antibody recognizes an accessible MMAE-associated epitope on the ADC. When paired with a target-specific or antibody-specific capture or detection reagent, it can support the measurement of payload-conjugated MMAE ADCs. The measured analyte is determined by the complete assay architecture, so Anti-MMAE binding alone does not distinguish payload-conjugated ADC, free MMAE, and other MMAE-containing species.